This site is intended for healthcare professionals

UK MHRA grants conditional approval for Exkivity in EGFR Exon20ins+ NSCLC.

Read time: 1 mins
Published:23rd Mar 2022

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Exkivity (mobocertinib), from Takeda, as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) locally advanced or metastatic non-small cell lung cancer.

The patients involved will have received prior platinum-based chemotherapy. EGFR Exon20ins+ NSCLC (non-small cell lung cancer) primarily affects younger people and non-smokers and carries a worse prognosis than other EGFR mutations.

Condition: NSCLC / EGFR
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights